Can a single injection reveal hidden kidney cancer?
NCT ID NCT07768306
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This early-stage trial tests an experimental imaging agent called 68Ga-NYM096 in 20 adults who have a kidney mass of uncertain nature seen on CT or MRI and are scheduled for surgery. The agent is designed to attach to a protein common on clear cell renal cell carcinoma cells, potentially making them visible on a PET scan. The study aims to check the agent's safety, how it moves through the body, and whether it can help identify cancer before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-NYM096 injection, an experimental imaging agent that targets a protein (CAIX) often found on clear cell renal cell carcinoma cells, given as a single intravenous injection before a PET scan.
- What this could lead to
- If successful, this could lead to a non-invasive PET imaging test that helps doctors tell cancerous from non-cancerous kidney masses without surgery, guiding treatment decisions.
- What could go wrong
- This is an early Phase 1 study with only 20 participants, so safety and diagnostic accuracy are not yet established. The imaging agent may not reliably distinguish cancer from benign tissue, and there are potential risks from radiation exposure and the injection itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Immune-Boosting drug combo targets Hard-to-Treat cancers
- New PET scan could spot hidden kidney cancer after treatment
- New drug combo may help save kidneys in High-Risk cancer patients
- New drug combo aims to shrink hard-to-treat tumors
- New imaging agent shows promise for kidney cancer detection
- New drug combo targets Hard-to-Treat cancers in early trial